Wegovy HD (semaglutide): A new high-dose option for adults managing obesity, showing significant weight loss in clinical trials.

Icotyde (icotrokinra): The first oral IL-23 blocker approved to treat moderate-to-severe plaque psoriasis, providing a new oral treatment choice.

Sotyktu (deucravacitinib): An oral TYK2 inhibitor now approved for treating active psoriatic arthritis, addressing inflammation with a convenient dosing regimen.

Awiqli (insulin isodec): The first once-weekly basal insulin for adults with type 2 diabetes.

Chapters:

• (00:21) - Intro
• (01:00) - Wegovy HD
• (02:10) - Icotyde
• (03:12) - Sotyktu
• (03:53) - Awiqli
• (04:32) - Outro

• X, Facebook, Youtube
• Sign up to our newsletters
• Download the app

• Zepbound KwikPen (tirzepatide): A new multidose Zepbound pen supplying 4 fixed weekly doses in one pen 
• Ozempic pill (semaglutide): Discover the upcoming once-daily oral option for adults with type 2 diabetes to manage blood sugar and cardiovascular risks.
• Rybrevant Faspro (amivantamab and hyaluronidase-lpuj): Explore the benefits of a simplified, monthly injectable regimen for EGFR-mutated NSCLC.
• Dupixent (dupilumab): The first approved therapy for allergic fungal rhinosinusitis, reducing the need for systemic steroids.
• Vybrique (sildenafil): A new oral film formulation of sildenafil for erectile dysfunction.
• Calquence + Venetoclax (acalabrutinib combination): This new all-oral regimen provides a targeted therapy for CLL, improving patient outcomes with a non-chemo approach.

Chapters:

• (00:00) - Intro
• (00:20) - Overview

• X, Facebook, Youtube
• Signup to our newsletters
• Download the app

• Darzalex Faspro (daratumumab and hyaluronidase-fihj) a new approval for use in combination with standard treatments for adults with newly diagnosed multiple myeloma.
• Yuvezzi (carbachol and brimonidine tartrate), a novel combination eye drop for presbyopia.
• Zycubo (copper histidinate), the first treatment for Menkes disease in children.
• Nexplanon (etonogestrel), a birth control implant with an extension of use for up to five years.
• Afrezza (insulin human), an inhaled insulin, with updated dosing guidance.

Chapters

• (00:00) - Intro
• (00:21) - Overview
• (00:47) - Darzalex
• (02:13) - Yuvezzi
• (03:06) - Zycubo
• (03:50) - Nexplanon
• (04:35) - Afrezza
• (05:09) - Outro

• X, Facebook, Youtube
• Signup to our newsletters
• Download the app

• Wegovy (semaglutide) tablet, the first oral GLP-1 for weight loss, with significant efficacy in patient trials.
• Myqorzo (aficamten), a long-awaited and major addition to obstructive hypertrophic cardiomyopathy treatment that improves exercise capacity.
• Exdensur (depemokimab-ulaa), a new long-term, add-on treatment for severe eosinophilic asthma with twice-yearly injections.
• Jaypirca (pirtobrutinib), a non-covalent BTK inhibitor whose approval has been extended to include chronic lymphocytic leukemia and small lymphocytic lymphoma.
• Lerochol (lerodalcibep-liga), a third-generation, PCSK9 inhibitor for high cholesterol self-administered via a monthly injection.
• Breyanzi (lisocabtagene maraleucel), a CAR T cell therapy with extended approval to include relapsed or refractory marginal zone lymphoma.

Chapters

• (00:00) - Intro
• (00:22) - Overview
• (00:34) - Wegovy
• (01:16) - Myqorzo
• (02:07) - Exdensur
• (02:56) - Jaypirca
• (03:31) - Lerochol
• (04:09) - Breyanzi
• (04:46) - Outro

• X, Facebook, Youtube
• Signup to our newsletters
• Download the app

• Keytruda (pembrolizumab), approved in combination with Padcev as neoadjuvant treatment for adults with muscle-invasive bladder cancer ineligible for cisplatin-containing chemotherapy, demonstrating a 60% reduction in event-free survival events.
• Epkinly (epcoritamab-bysp) plus rituximab and lenalidomide, approved for adults with relapsed or refractory follicular lymphoma, showing a 79% reduction in disease progression risk through T-cell engagement with malignant B-cells.
• Darzalex Faspro (daratumumab and hyaluronidase-fihj), now the first and only approved treatment for patients with high-risk smoldering multiple myeloma, significantly slowing disease progression.
• Eylea HD (aflibercept ophthalmic), approved for macular edema following retinal vein occlusion with extended up to every 8-week dosing after initial treatment, maintaining visual acuity with less frequent administration.
• Caplyta (lumateperone), newly approved as an add-on therapy for adults with major depressive disorder, enhancing outcomes when used alongside existing antidepressants.

Chapters:

• (00:00) - Intro
• (00:37) - Discussion points
• (00:47) - Keytruda
• (01:20) - Epkinly
• (02:10) - Darzalex
• (02:47) - Eylea HD
• (03:14) - Caplyta
• (03:43) - Key takeaways
• (04:02) - Outro

• X, Facebook, Youtube
• Signup to our newsletters
• Download the app

• Rybelsus (semaglutide): Exploring its new role in cardiovascular risk reduction for adults with type 2 diabetes.
• Zoryve (roflumilast): A breakthrough steroid-free topical treatment for eczema in young children.
• Gazyva (obinutuzumab): Approved for lupus nephritis, offering new hope for managing this serious kidney ailment.
• Lynkuet (elinzanetant): A hormone-free option for alleviating hot flashes due to menopause.
• Lasix ONYU (furosemide injection): Introducing an at-home infusion method for heart failure patients dealing with edema.
• Jascayd (nerandomilast): A new approval to combat the progression of idiopathic pulmonary fibrosis.

Chapters:

• (00:00) - Intro
• (00:40) - Rybelsus
• (01:36) - Zoryve Cream
• (02:17) - Gazyva
• (02:51) - Lynkuet
• (03:01) - Lasix ONYU
• (03:44) - Jascayd
• (04:16) - Outro

• X, Facebook, Youtube
• Signup to our newsletters
• Download the app

• Rhapsido (remibrutinib) for the management of difficult chronic spontaneous urticaria in adults still experiencing symptoms despite antihistamine therapy.
• Palsonify (paltusotine) introduces a groundbreaking once-daily oral option for acromegaly, offering rapid control of growth hormone levels.
• Inluriyo (imlunestrant), a significant development for treating ESR1-mutated breast cancer in patients who have experienced disease progression after endocrine therapy.
• Forzinity (elamipretide hydrochloride) provides hope for children with Barth syndrome by improving muscle strength through mitochondrial support.
• Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph), a quicker subcutaneous option for pembrolizumab administration, simplifying immunotherapy for melanoma and non-small cell lung cancer patients.

Chapters

• (00:25) - Intro
• (00:51) - Rhapsido
• (01:47) - Palsonify
• (02:48) - Inluriyo
• (03:33) - Forzinity
• (04:09) - Keytruda Qlex
• (04:45) - Outro

• X, Facebook, Youtube
• Signup to our newsletters
• Download the app

• Wegovy (semaglutide) for metabolic liver disease: Now indicated for metabolic dysfunction-associated steatohepatitis (MASH) in adults, offering a new treatment pathway for this progressive liver condition.
• Tonmya (cyclobenzaprine) for fibromyalgia: A potent sublingual treatment, provides hope in managing fibromyalgia's chronic pain and sleep disturbances.
• Ajovy (fremanezumab) for pediatric migraines: The first anti-CGRP therapy approved for migraine prevention in children, opening new avenues for managing this debilitating condition.
• Repatha (evolocumab) for cardiovascular risk: Expanded use in adults at risk for major cardiovascular events, even absent diagnosed cardiovascular disease.
• Brinsupri (brensocatib) for bronchiectasis: Provides a novel oral option for reducing flares in non-cystic fibrosis bronchiectasis, promising symptom relief.

Chapters:

• (00:00) - Intro
• (00:41) - Wegovy
• (01:41) - Tonmya
• (02:32) - Ajovy
• (03:19) - Repatha
• (03:57) - Brinsupri
• (04:26) - Outro

• X, Facebook, Youtube
• Signup to our newsletters
• Download the app

• Ekterly (sebetralstat), approved as an oral on-demand treatment for hereditary angioedema (HAE) attacks in patients 12 years and older, providing symptom relief in just 1.6 hours compared to 6.7 hours with placebo.
• Anzupgo (delgocitinib), the first steroid-free topical treatment approved in the U.S. for moderate to severe chronic hand eczema in adults, working as a pan-Janus kinase inhibitor with twice-daily application to affected areas.
• Kisunla (donanemab-azbt), now available with an updated once-monthly dosing regimen for early symptomatic Alzheimer's disease, showing a 41% reduction in ARIA-E (amyloid-related imaging abnormalities with edema) at 24 weeks while targeting and removing beta-amyloid plaques in the brain.

Chapters

• (00:00) - Intro
• (00:24) - Overview
• (00:47) - Angioedema
• (01:10) - Ekterly
• (01:51) - Anzupgo
• (02:54) - Kisunla
• (03:45) - Outro

• X, Facebook, Youtube
• Signup to our newsletters
• Download the app

• Dupixent (dupilumab), newly approved for treating bullous pemphigoid in adults—a painful autoimmune skin disorder primarily affecting patients over 65.
• Mavyret (glecaprevir/pibrentasvir) for acute hepatitis C virus treatment in children as young as 3 years old.
• Yeztugo (lenacapavir), a groundbreaking twice-yearly injectable HIV prevention therapy offering a 99.9% effectiveness rate in clinical trials.
• Enflonsia (clesrovimab-cfor), a new RSV prevention option for neonates and infants that provides season-long protection with a single injection.
• Ibtrozi (taletrectinib), an oral targeted therapy approved for ROS1-positive non-small cell lung cancer in patients with locally advanced or metastatic disease.

Chapters:

• (00:00) - Intro
• (00:24) - Overview
• (00:45) - Dupixent
• (01:38) - Mavyret
• (02:14) - Yeztugo
• (03:14) - Enflonsia
• (03:54) - Ibtrozi
• (04:26) - Outro

• X, Facebook, Youtube
• Signup to our newsletters
• Download the app